Item 5. Other Information

On  June 25, 2026, Quan Vu, our Chief Financial Officer, adopted a trading arrangement (the “Vu 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Vu Rule 10b5-1 Trading Plan provides for the sale of up to 615 shares of Common Stock. The Vu Rule 10b5-1 Trading Plan will terminate on  May 31, 2027, unless terminated earlier pursuant to the terms of the Vu Rule 10b5-1 Trading Plan.

On  June 25, 2026, Chandler Robinson, our Chief Executive Officer, adopted a trading arrangement (the “Robinson 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Robinson Rule 10b5-1 Trading Plan provides for the sale of up to 47,309 shares of Common Stock. The Robinson Rule 10b5-1 Trading Plan will terminate on  May 31, 2027, unless terminated earlier pursuant to the terms of the Robinson Rule 10b5-1 Trading Plan.

On  May 28, 2026, Christopher Starr, our Executive Chairman of the Board of Directors, adopted a trading arrangement (the “Starr 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Starr Rule 10b5-1 Trading Plan provides for the sale of up to 16,800 shares of Common Stock. The Starr Rule 10b5-1 Trading Plan will terminate on  February 20, 2027, unless terminated earlier pursuant to the terms of the Starr Rule 10b5-1 Trading Plan.

On  May 27, 2026, Kim Tsuchimoto, a member of the Board of Directors, adopted a trading arrangement (the “Tsuchimoto 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Tsuchimoto Rule 10b5-1 Trading Plan provides for the sale of up to 16,360 shares of Common Stock. The Tsuchimoto Rule 10b5-1 Trading Plan will terminate on  July 31, 2027, unless terminated earlier pursuant to the terms of the Tsuchimoto Rule 10b5-1 Trading Plan.

On  May 27, 2026, Patrice Rioux, our Chief Medical Director, adopted a trading arrangement (the “Rioux 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Rioux Rule 10b5-1 Trading Plan provides for the sale of up to 1,380 shares of Common Stock. The Rioux Rule 10b5-1 Trading Plan will terminate on  December 14, 2026, unless terminated earlier pursuant to the terms of the Rioux Rule 10b5-1 Trading Plan.

On  May 26, 2026, Raymond Anderson, a member of the Board of Directors, adopted a trading arrangement (the “Anderson 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Anderson Rule 10b5-1 Trading Plan provides for the sale of up to 9,425 shares of Common Stock. The Anderson Rule 10b5-1 Trading Plan will terminate on  May 31, 2027, unless terminated earlier pursuant to the terms of the Anderson Rule 10b5-1 Trading Plan.